0.270
0.01 (3.85%)
| Penutupan Terdahulu | 0.260 |
| Buka | 0.265 |
| Jumlah Dagangan | 2,186,554 |
| Purata Dagangan (3B) | 2,618,974 |
| Modal Pasaran | 393,009,312 |
| Harga / Jualan (P/S) | 1.32 |
| Harga / Buku (P/B) | 2.28 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Jul 2025 - 4 Aug 2025 |
| Margin Operasi (TTM) | -839.24% |
| EPS Cair (TTM) | -0.030 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 49.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.98% |
| Nisbah Semasa (MRQ) | 18.86 |
| Aliran Tunai Operasi (OCF TTM) | -44.92 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -31.56 M |
| Pulangan Atas Aset (ROA TTM) | -20.35% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.45% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (AU) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | IMMUTEP FPO [IMM] | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 3.0 |
| Purata | 2.50 |
|
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.32% |
| % Dimiliki oleh Institusi | 42.39% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |